The report titled “The US Pharmaceutical Market Outlook to 2016 – Evolving Opportunities in the Biologics Segment” provides a comprehensive analysis on the Pharmaceutical market in the US covering various aspects such as market size of the pharmaceutical industry, market segmentation by Branded and Generic drugs, and Prescribed and OTC drugs and Biologics and specialty drugs segments. The report also provides information on the government regulations, export and imports of pharmaceuticals and medicines. The report also entails competitive landscape and profiles of the major players operating in the industry. The future projections are included to provide an insight on the prospects in the US pharmaceutical industry. http://bharatbook.com/market-research-reports/healthcare-market-research-report/the-us-pharmaceutical-market-outlook-to-2016-evolving-opportunities-in-the-biologics-segment.html
 
 The US Pharmaceutical market is the largest pharmaceutical market in the world which has registered a marginal slowdown in the growth rate over the period. The slowing growth rate can be attributed to an increasing number of drugs losing its patent security and surrogated by generic equivalents. In terms of sales value, the US pharmaceutical industry has recorded consistent growth at a 5 year CAGR of 3.2% over the period. The sales of Pharmaceuticals in the US grew from USD ~ billion in 2005 to USD ~ billion in 2010. Industry Analysis
 
 Branded drugs hold the major market share in the total pharmaceutical drugs sales in the US. In 2010, branded drugs accounted for ~ of the total drugs sold, but this market share decreased over the period from ~ in 2005. The sales of branded drugs grew from USD ~billion in 2005 to USD ~ billion in 2010 at a CAGR of ~. Generic drugs, which showcased a growth in the market share over the period from ~ share in 2005 to ~ in 2010 and posted sales of USD ~ billion, which has grown at a 5 year CAGR of 9.4% from sales worth of USD ~ billion in 2005.
 
 The biopharmaceutical industry is one of the most research concentrated industries in the US. The expenditure on biopharmaceutical research and development has showcased a dependable growth over the period. The expenditure has grown from USD ~ billion in 2005 to USD ~ billion in 2010 at a CAGR of 5.4%. Avastin, Rituxan, Enbrel and Remicade among the world’s top selling biologics and each recorded sales above USD ~ billion in the US in 2010. Bristol-Myers Squibb is the largest company in the US in terms of biopharmaceutical drugs sales. The company held a market share of ~% and recorded sales of USD ~ billion. The US biologic drugs market is estimated to grow at a 5 year CAGR of 8.1% from 2011 to reach USD ~ billion by 2016.
 
 The US pharmaceutical industry is expected to grow over the period at a CAGR of 4.8% with projected sales of USD ~ billion in 2015. It is estimated that the research and development productivity will increase and will trigger the growth in the market. Additionally the companies will focus on developing pharmaceutical drugs for personalized healthcare.
 
 The US pharmaceutical industry witnessed revenues worth of USD ~ billion in 2011. Pfizer is the largest company with a market share of ~ and sales of USD ~ billion in 2011. Pfizer’s blockbuster drug, Lipitor played a major role in helping the company secure its number one position.
 
 Key Topics Covered in the Report:
 * The market size of US pharmaceutical industry by revenue
 * Market segmentation on the basis of branded and generic drugs, and prescribed and OTC drugs.
 * Import and Exports of pharmaceuticals and medicines
 * Market size, market segmentation competitive landscape and future outlook of the US biologic drugs market
 * Government regulations pertaining to the industry.
 * Trends and developments pertaining to the industry.
 * Competitive Landscape and Profile of the major players
 * Cause and Effect Relationship Analysis between industry factors and expected US pharmaceutical industry prospects
 * Future outlook and projections of the sales of pharmaceutical drugs and its segments in the US till 2015.
 * Macroeconomic and industry factors affecting the industry
 
 1. The US Pharmaceutical Industry Introduction
 2. The US Pharmaceutical Market Size, 2005-2010
 3. Top 50 Pharmaceutical Drugs in the US
 4. The US Regulations Pertaining to the Pharmaceutical Industry
 General Overview
 Health Care Reform
 Patent
 5. The US Pharmacy Distribution and Reimbursement System
 6. The US Pharmaceutical Market Segmentation
 6.1. By Generic and Branded Drugs, 2005-2010
 6.1.1. Generic Drugs Competitive Landscape, 2011
 6.2. By Prescribed and Over the Counter Drugs (OTC), 2005-2010
 6.2.1. Prescribed Drugs Market Segmentation, 2006-2010
 6.2.1.1. Top Therapeutic Classes in the US by Prescriptions Dispensed and Spending, 2006-2010
 6.2.1.2. The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, 2005-2010
 6.2.1.3. The US Prescription Drug Competitive Landscape, 2010
 6.2.1.4. Top US Pharmacies by Total Prescription Revenues, 2011
 6.2.2. OTC Drugs Market Segmentation, 2007-2010
 6.3. The US Biologics/Biopharmaceutical Market
 6.3.1. The US Biologics/Biopharmaceutical Market Size By Value, 2006-2011
 
 For more information kindly visit :
 The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment
 
 Or
 
 Bharat Book Bureau
 Tel: +91 22 27810772 / 27810773
 Fax: + 91 22 27812290
 Email: info@bharatbook.com
 Website: www.bharatbook.com
 Follow us on twitter: http://twitter.com/#!/Sandhya3B